The research team of Prof.
Non-blood cord blood transplantation is an important means to cure hematological malignancies, hematopoietic failure diseases, congenital immunodeficiency diseases and some genetic metabolic diseases, and the incidence of chronic graft-versus-host disease after transplantation is low and mild, and patients The quality of life is high
The research team analyzed the peripheral blood of recipients after non-blood cord blood transplantation and found that there was a significant increase in peripheral blood mononuclear cells in PES patients.
On the basis of mechanism research, the clinical team carried out a single-arm open clinical trial of tocilizumab (a monoclonal antibody that specifically blocks IL-6 receptor) in the treatment of severe PES patients, and found that tocilizumab was used for intervention Treatment can significantly control the clinical symptoms of severe PES patients and improve the survival rate of patients
The research lasted for nearly 8 years, and some of the results have provided important practical guidance significance for the school’s proposal and implementation of an immunotherapy program for severely ill patients with new coronary pneumonia (tocilizumab treatment program)
Related paper information: https://doi.
https://doi.
org/10.
1038/s41467-021-24412-1 https://doi.
org/10.
1038/s41467-021-24412-1
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
